GP1BA and metabolic dysfunction-associated steatohepatitis: Further, platelet-derived GPIbα was found to be a critical mediator and potential interventional target for the development of MASH and subsequent liver cancer, and antiplatelet therapy (aspirin/clopidogrel, and ticagrelor) may prevent the development of MASH and subsequent liver cancer through suppression of intrahepatic platelet accumulation and cytokine and chemokine release (Malehmir et al., 2019).